CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Interferon-2A +4 moredrug
Likely dose
Adriamycin 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01404936
NCT01404936Phase 2Completed
CompareCT.gov

A Phase II Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) for Patients With Hodgkin's Disease

M.D. Anderson Cancer Center·interventional·Posted Jul 28, 2011·Updated Feb 1, 2013

In Brief

A Phase 2 clinical trial evaluating Interferon-2A, Adriamycin, and 3 other interventions for Lymphoma. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This is a clinical research study of interferon (IFN) plus chemotherapy with the standard combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD improves the immune response against Hodgkin's disease, and will determine whether the toxicity of ABVD is increased by adding IFN.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsSchering-Plough

Timeline

Phase 2CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 28, 2011
Enrollment StartJul 1, 1996
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 15.4 yearsPosted 14.9 years ago

Interventions

Interferon-2Adrug

4 (x106 IU/m\^2) subcutaneously on days 1-4.

Adriamycindrug

25 mg/m\^2 by vein on day 4.

Bleomycindrug

10 mg/m\^2 by vein on day 4.

Velbandrug

6 mg/m\^2 by vein on day 4.

Dacarbazinedrug

375 mg/m\^2 by vein on day 4.